Surgical Science Sweden AB Signals Resilient Underlying Growth

Surgical Science Sweden AB ((SE:SUS)) has held its Q1 earnings call. Read on for the main highlights of the call.

Surgical Science Sweden AB’s latest earnings call struck a cautiously optimistic tone, with management emphasizing solid underlying demand and improving profitability once currency swings are stripped out. Investors heard a story of resilient growth, strong cash generation and expanding product and robotics pipelines, tempered by FX headwinds and known license revenue pressure in the coming years.

Underlying Growth Masks Reported Revenue Decline

Reported sales slipped about 6% to roughly SEK 235–236 million, but management stressed that, after adjusting for a sharp USD-related currency drag, the underlying business grew 4%. This divergence underscores that operational demand is intact even as headline numbers look softer, an important nuance for investors gauging the company’s real growth trajectory.

Cash Flow Strength and Debt-Free Balance Sheet

Operating activities generated SEK 65 million in cash versus a SEK 5 million outflow a year earlier, flipping the company into a net positive cash flow of SEK 51 million for the quarter. With SEK 668 million in cash on hand and no debt, Surgical Science enters a more volatile macro and FX environment with significant financial flexibility to fund expansion and absorb shocks.

Margins at Target on FX-Adjusted Basis

Adjusted EBIT came in at SEK 28 million, representing a 12% margin on reported figures, but climbed to SEK 42 million or roughly 16% when FX effects are removed. Management described that FX-adjusted level as being right at their target margin, suggesting that profitability levers are working even if currency volatility temporarily suppresses reported margins.

Educational Segment and EMEA Drive Top-Line Momentum

Educational Products delivered 6% reported growth, which translates to a robust 14% increase in local currencies once FX is excluded. EMEA was the standout region with revenue surging more than 80%, fueled by strong demand in Eastern Europe, while the U.K. logged one of its best quarters ever, already surpassing its total 2025 sales in sterling terms.

Ultrasound Adoption and New Product Launches

The ultrasound business delivered a strong quarter, benefitting from accelerating adoption and a steady stream of product innovations. New launches in endovascular simulation, including pulmonary embolism scenarios and ICE 3D capabilities, as well as the first products on the shared platform post-Intelligent Ultrasound integration, broaden the company’s clinical training offering.

Diversifying Robotics Revenues Beyond a Single Partner

Despite short-term swings in license income, executives highlighted that robotics-related revenue is increasingly coming from multiple customers rather than relying solely on Intuitive. The company is now working on solutions for most of the top 20 robotics firms, and regulatory approvals across the industry are expected to boost long-term demand for training and simulation tools.

Operational Efficiency and Margin Improvement Measures

Management is pushing through price increases, including one implemented in April, while simultaneously focusing on gross-margin enhancement and scale benefits. A new production facility in Tel Aviv, slated to go live in the second quarter after SEK 6 million of Q1 investment, is expected to lower unit costs and support more efficient manufacturing as volumes grow.

High Customer Retention in Medical Device Development

In the Medical Device segment, over 70% of customers in active development projects are repeat buyers, reflecting strong satisfaction and stickiness in this business line. This high level of recurrence suggests a durable pipeline of future work and underpins the recurring nature of development demand, even if individual projects can be lumpy quarter to quarter.

Currency Headwinds Weigh on Reported Performance

USD weakness was a major drag, with the average Q1 exchange rate around 14% lower year on year and roughly 70% of revenue denominated in USD. Management estimated that FX effects cut reported sales by about 6% and reduced gross margin by roughly 2.2 percentage points, contributing to a reported gross margin of 66% versus 69% in the comparable period.

Intuitive Contract Reversion Hits Robotics Licenses

Robotics license revenue declined to SEK 68 million from SEK 84 million a year ago, a 19% drop in SEK terms that narrows to about 8% in USD, highlighting the role of FX. The company reiterated that changes in the commercial structure with Intuitive will reduce 2026 license revenue by an estimated SEK 60–90 million versus 2025, a known headwind investors need to factor into midterm forecasts.

Regional Weakness in Americas and APAC

Overall revenue fell 6%, with the Americas region particularly weak, posting a 24% reported decline or about 10% lower excluding FX due to slower buying decisions and hesitation among U.S. customers. APAC revenue dropped 25%, driven largely by softer sales in China and the absence of a large Pakistan order that boosted the prior-year comparison.

China Faces Structural Challenges

The company flagged structural headwinds in China, where government preference for local manufacturers is eroding competitiveness for its simulators. This dynamic led to year-on-year sales declines in the quarter and is prompting a strategic rethink, including efforts to increase local presence to mitigate policy-driven disadvantages.

Gross Margin and EBIT Under Pressure

Reported gross margin slipped to 66% from 69% on a comparable basis, reflecting both FX and other cost pressures, while EBIT landed at SEK 23 million for a 10% margin. Additional operating hits included a negative currency revaluation of just over SEK 5 million compared with a SEK 2 million positive effect last year and tariff costs of roughly SEK 2.4 million.

Lumpiness in Medical Device and Simulator Sales

The Medical Device segment was relatively quiet, with development revenue of SEK 14 million and simulator sales of SEK 20 million, emphasizing the inherent lumpiness of this project-driven business. Management noted that milestone timing, including a Southeast Asian project with only SEK 2 million recognized this quarter, weighed on near-term comparisons but does not alter the underlying opportunity.

Outlook and Guidance: Margin Recovery Amid Known Headwinds

Looking ahead, Surgical Science reaffirmed near-term guidance centered on rebuilding margins while acknowledging the SEK 60–90 million license revenue headwind in 2026 tied to the Intuitive contract change. Even with reported Q1 sales down 6%, FX-adjusted revenue growth, improving EBIT margins, strong cash flow, ongoing price actions and the Tel Aviv facility ramp-up underpin management’s confidence in achieving its 2027 financial targets.

Surgical Science’s earnings call painted a picture of a company managing through currency volatility and contract transitions while preserving core growth and profitability drivers. For investors, the key takeaway is that underlying demand, cash strength and a broadening robotics and ultrasound pipeline offset near-term regional softness and license headwinds, supporting a constructive long-term equity story.